Original news and analysis on international IP policy
IRVINE, CALIFORNIA – Experts gathered here last week addressed the question of – one year later - what does the United States Supreme Court’s decision on human gene patents mean for scientific research and patent policy?
Infojustice.org writes: Last week, 23 civil society groups released the African Declaration on Internet Rights and Freedoms at the Internet Governance Forum, infojustice.org reports. The declaration is organized around twelve key principles, including Freedom of Expression and the Right to Information and Open Data.
European Union governments may allow libraries to digitise books in their collection without rights owners' consent in order to make them available at electronic reading posts, the European Court of Justice (ECJ) said on 11 September. If library users want to print works out on paper or store them on a USB stick, however, rights holders must be fairly compensated.
The structure of new European Commissioners and top officials was announced today, showing changes to the handling on intellectual property issues and many others.
Applicants to the European “Innovation Communities” initiative have until 10 September to submit joint innovation proposals in the areas of healthy aging and raw materials. The aim is to create new organisations compliant with the European grant programme Horizon 2020, which will operate under flexible intellectual property rights’ policies in collaborative innovation projects.
The world and the global health community have been taken by surprise by the worst outbreak of Ebola so far. The World Health Organization today (5 September) said a vaccine could be available in November 2014 if proven safe. So far, according to the WHO, intellectual property issues have not acted as a barrier to accessing potential treatments and vaccines, and the focus for now is on emergency measures to find health solutions.
The World Health Organization this week is holding a consultation on potential Ebola therapies and vaccines.
Biosimilar medicines might prove to be a new reservoir for innovation for the pharmaceutical industry. However, the complexity of their manufacture needs a stringent regulatory framework, according to the industry.
Faced with the worst outbreak of Ebola since its discovery some 40 years ago, the world is scrambling for treatments. A World Health Organization-convened panel of experts has decided it is ethical to use experimental treatments. Why is there no treatment available even after 40 years? Market failure, not intellectual property rights, says the WHO.
Drug regulatory authorities are meeting this week in Rio de Janeiro, Brazil to discuss global regulatory issues such as vaccine regulation, falsified products, and pharmacovigilance. A “pre-conference” focused on biosimilars, with civil society warning on barriers to access to those products.
The Washington Post story, How patent reform’s fraught politics have left USPTO still without a boss (July 30), is a vivid account of how patent reform has divided the US economy, preempting a possible replacement for David Kappos who stepped down 18 months ago. The division is even bigger than portrayed. Universities have lined up en masse to oppose reform, while main street businesses that merely use technology argue for reform. Reminiscent of the partisan divide that has paralyzed US politics, this struggle crosses party lines and extends well beyond the usual inter-industry debates. Framed in terms of combating patent trolls through technical legal fixes, there lurks a broader economic concern – to what extent ordinary retailers, bank, restaurants, local banks, motels, realtors, and travel agents should bear the burden of defending against patents as a cost of doing business, writes Brian Kahin.
Intellectual Property Watch is pleased to announce a joint internship opportunity with the DiploFoundation/Geneva Internet Platform in Geneva, covering events and issues related to internet governance.